1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Chemclin Diagnostics Co., Ltd.

Chemclin Diagnostics Co., Ltd.

688468.SS
Chemclin Diagnostics Co., Ltd.CN flagShanghai Stock Exchange
6.13
CNY
-0.05
- -
2.46BMarket Cap
Chemclin Diagnostics Co., Ltd.
688468.SS
(Shanghai Stock Exchange)

Recent

price

6.13

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
1.26
1.18
1.22
1.16
1.12
1.1
0.83
1.03
Revenue per Share
- -
- -
0.39
0.33
0.37
0.38
0.37
0.32
0.11
0.21
Basic EPS, GAAP
- -
- -
0.41
0.19
0.3
0.3
-0.32
0.15
0.06
-0.22
Free Cash Flow per Basic Share
- -
- -
0.12
0.3
- -
0.17
0.35
0.13
0.14
0.15
Dividend per Share
- -
- -
1.42
1.49
1.83
1.93
1.93
2.13
2.11
2.26
Book Value per Share
- -
- -
1.98
2.03
2.88
2.98
2.99
3.07
3.06
3.3
Tangible Book Value per Share
- -
- -
360
355
386
402
398
397
399
364
Basic Weighted Avg Shares
319
366
455
418
471
465
445
436
333
375
Sales/Revenue/Turnover
-133.55
-114.01
32.77
30.08
31.35
31.97
33.19
28.85
13.99
19.83
Operating Margin (%)
38
39
42
42
53
51
49
54
57
- -
Depreciation Expense
-435
-424
141
117
143
153
147
127
44
75
Net Income, GAAP
- -
- -
11.93
13.6
11.98
13.95
11.28
7.86
11.86
7.75
Effective Tax Rate (%)
-136.61
-115.9
30.92
27.98
30.32
32.8
33.09
29.13
13.2
19.92
Profit Margin (%)
357
496
594
594
970
968
908
884
602
873
Working Capital
- -
- -
- -
7
13
2
228
224
183
229
LT Debt
647
775
867
887
1,279
1,381
1,389
1,416
1,411
1,391
Total Equity
- -
- -
15.88
12.23
11.69
9.34
8.57
7.01
2.47
4.18
Return on Invested Capital (%)
- -
- -
229.03
22.24
22.57
20.15
16.49
12.56
4.57
7.67
Return on Capital (%)
- -
- -
- -
22.45
23.1
20.6
19.07
15.72
5.2
9.24
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
25
29
30
LT Borrowings
200
200
200
LT Finance Leases
24
30
29
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
401
401
401
Market Capitalization
2,630
2,709
2,676

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,068
1,050
1,017
Cash, Cash Equivalents & STI
909
887
854
Accounts Receivable, Net
20
19
18
Inventories
109
111
113
Total Current Liabilities
183
147
143
Payables & Accruals
- -
- -
- -
ST Debt
25
29
30
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
10.85%
-0.38%
Free Cash Flow
- -
-68.6%
-60.28%
Net Income, GAAP
- -
-10.75%
-65.44%
Sales/Revenue/Turnover
- -
-3.73%
-23.75%
Total Cash Common Dividend
- -
- -
2.83%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
111
114
118
93
436
2025
81
83
72
- -
333
2026
73
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
- -
- -
- -
0.32
2025
0.04
- -
- -
- -
0.11
2026
0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.13
2025
- -
- -
- -
- -
0.14
2026
- -
- -
- -
- -
- -
Similar Companies
Fielmann Group AG (FLMNY)
Ypsomed Holding AG (YPHDF)
LAMEDITECH Co., Ltd. (462510.KQ)
AI Maverick Intel, Inc. (AIMV)
QMed, Inc. (QMED)
ToolGen Incorporated (199800.KQ)
Business
Chemclin Diagnostics Co., Ltd. (688468.SS) develops, manufactures, and sells clinical chemiluminescence immunoassay diagnostic reagents and instruments. The company offers LiCA series products based on proprietary light-initiated chemiluminescence immunoassay technology, including reagents and automated analyzers such as LiCA 500, LiCA 800, and LiCA 1500 for infectious diseases including hepatitis B, hepatitis C, AIDS, syphilis, hepatitis A, and hepatitis E; tumor markers; thyroid hormones; reproductive endocrine hormones; cardiac markers; and inflammation markers; as well as CC series products based on enzymatic chemiluminescence for similar applications. It operates primarily in China with global aspirations, targeting clinical laboratories and healthcare providers. Founded in 2007 and headquartered in Beijing, the company listed on the Shanghai Stock Exchange STAR Market in April 2021 and maintains a strong focus on R&D, recognized as a national high-tech enterprise and "Little Giant" in specialized new fields. Recent developments include advancements in thyroid function testing collaborations, such as ongoing tripartite projects for FT3 and FT4 assays expected to complete in early 2025, alongside shareholder reductions by key investors like Hengqin Junlian Zhikang.